Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, PanTher Therapeutics is raising $7,334,474.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Laura Indolfi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About PanTher Therapeutics

At PanTher Therapeutics, we aim to provide superior technologies for revolutionizing the treatment of inoperable locally advanced solid tumors. PanTher designed its novel delivery method to potentially eliminate the toxicity and debilitating side effects that chemo agents can produce when delivered systemically through traditional IV or oral administration. By changing the route of administration to target just the tumor, PanTher is designed to increase the amount of drug reaching the intended destination with the aim to enhance therapeutic efficacy. Eliminating adverse outcomes may also help to lower healthcare costs. The first indication will be Pancreatic Cancer, one of the most lethal diseases where excruciating symptoms arise from the primary mass invading nearby vital organs. The company is completing pre-clinical studies prior to initiate human trials and exploring opportunities for partnerships to expand product pipeline.

To learn more about PanTher Therapeutics, visit http://www.panthertx.com/

Contact:
Laura Indolfi, Chief Executive Officer
857-413-1698
https://www.linkedin.com/in/lauraindolfi/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved